The Latin America, Middle East and Africa Neutropenia Treatment Market is expected to witness market growth of 7.4% CAGR during the forecast period (2020-2026).
Neutropenia is a disease in which the number of white blood cells (neutrophils) in the bloodstream is reduced, decreasing the body 's capacity to combat infections. Neutropenia is classified as an absolute neutrophil count (ANC) below 1500 per microliter (1500/microL); severe neutropenia is defined as an ANC below 500/microL.
The neutropenia market is expected to grow significantly in the future due to an increase in the incidence of cancer cases. In addition, a surge in R&D activities by companies to improve novel neutropenia treatment is projected to fuel demand growth throughout the forecast period. Nonetheless, the high cost of neutropenia treatment and the stringent rules and regulations for product approvals are likely to impede the growth of the market for neutropenia treatment during the forecast period. On the contrary, the transition from branded drugs to low-cost biosimilars is expected to provide market players with remunerative opportunities.
One of the new developments to gain momentum in the global neutropenia treatment market is the introduction of small molecules. The development of Plinabulin, a small molecule developed by BeyondSpring Pharmaceuticals with immune-boosting effects, is expected to revolutionize the therapeutic regimen for neutropenia. In addition to the immune-boosting effects, the Phase II studies have revealed much more beneficial anti-cancer effects of this molecule.
Based on Distribution channel, the market is segmented into Retail pharmacies, Hospital pharmacies and Online pharmacies. Based on Treatment, the market is segmented into Colony-stimulating factor, Antibiotics, Antifungals and Antivirals. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Amgen, Inc., Novartis AG, Pfizer, Inc., Teva Pharmaceuticals Industries Ltd., BeyondSpring, Inc., Spectrum Pharmaceuticals, Inc., Kyowa Kirin Co., Ltd. (Kirin Company), Mylan N.V., Cellerant Therapeutics, Inc., and Partner Therapeutics, Inc.
Scope of the Study
Market Segmentation:
By Distribution Channel
By Treatment
By Country
Companies Profiled
Unique Offerings from the Publisher
Neutropenia is a disease in which the number of white blood cells (neutrophils) in the bloodstream is reduced, decreasing the body 's capacity to combat infections. Neutropenia is classified as an absolute neutrophil count (ANC) below 1500 per microliter (1500/microL); severe neutropenia is defined as an ANC below 500/microL.
The neutropenia market is expected to grow significantly in the future due to an increase in the incidence of cancer cases. In addition, a surge in R&D activities by companies to improve novel neutropenia treatment is projected to fuel demand growth throughout the forecast period. Nonetheless, the high cost of neutropenia treatment and the stringent rules and regulations for product approvals are likely to impede the growth of the market for neutropenia treatment during the forecast period. On the contrary, the transition from branded drugs to low-cost biosimilars is expected to provide market players with remunerative opportunities.
One of the new developments to gain momentum in the global neutropenia treatment market is the introduction of small molecules. The development of Plinabulin, a small molecule developed by BeyondSpring Pharmaceuticals with immune-boosting effects, is expected to revolutionize the therapeutic regimen for neutropenia. In addition to the immune-boosting effects, the Phase II studies have revealed much more beneficial anti-cancer effects of this molecule.
Based on Distribution channel, the market is segmented into Retail pharmacies, Hospital pharmacies and Online pharmacies. Based on Treatment, the market is segmented into Colony-stimulating factor, Antibiotics, Antifungals and Antivirals. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Amgen, Inc., Novartis AG, Pfizer, Inc., Teva Pharmaceuticals Industries Ltd., BeyondSpring, Inc., Spectrum Pharmaceuticals, Inc., Kyowa Kirin Co., Ltd. (Kirin Company), Mylan N.V., Cellerant Therapeutics, Inc., and Partner Therapeutics, Inc.
Scope of the Study
Market Segmentation:
By Distribution Channel
- Retail pharmacies
- Hospital pharmacies and
- Online pharmacies
By Treatment
- Colony-stimulating factor
- Antibiotics
- Antifungals and
- Antivirals
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Companies Profiled
- Amgen, Inc.
- Novartis AG
- Pfizer, Inc.
- Teva Pharmaceuticals Industries Ltd.
- BeyondSpring, Inc.
- Spectrum Pharmaceuticals, Inc.
- Kyowa Kirin Co., Ltd. (Kirin Company)
- Mylan N.V.
- Cellerant Therapeutics, Inc.
- Partner Therapeutics, Inc.
Unique Offerings from the Publisher
- Exhaustive coverage
- Highest number of market tables and figures
- Subscription based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. LAMEA Neutropenia Treatment Market by Distribution channel
Chapter 4. LAMEA Neutropenia Treatment Market by Treatment
Chapter 5. LAMEA Neutropenia Treatment Market by Country
Chapter 6. Company Profiles
Companies Mentioned
- Amgen, Inc.
- Novartis AG
- Pfizer, Inc.
- Teva Pharmaceuticals Industries Ltd.
- BeyondSpring, Inc.
- Spectrum Pharmaceuticals, Inc.
- Kyowa Kirin Co., Ltd. (Kirin Company)
- Mylan N.V.
- Cellerant Therapeutics, Inc.
- Partner Therapeutics, Inc.
Methodology
LOADING...
